-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Plogosertib in Triple-Negative Breast Cancer (TNBC) Drug Details: Plogosertib is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1206 in Sarcomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BI-1206 in Sarcomas Drug Details: BI-1206 is under development for the treatment of solid tumors...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trilaciclib in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trilaciclib in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Trilaciclib in Metastatic Transitional (Urothelial) Tract Cancer Drug Details:Trilaciclib (Cosela)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lonigutamab Ugodotin in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lonigutamab Ugodotin in Graves' Ophthalmopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Lonigutamab Ugodotin in Graves' Ophthalmopathy Drug Details:VB-421 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abatacept in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abatacept in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Abatacept in Type 1 Diabetes (Juvenile Diabetes) Drug Details:Abatacept (CTLA4-Ig)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1206 in B-Cell Chronic Lymphocytic Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1206 in B-Cell Chronic Lymphocytic Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1206 in B-Cell Chronic Lymphocytic Leukemia Drug Details: BI-1206...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VB-119 in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VB-119 in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VB-119 in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: VB-119 is...
-
Company Insights
Innovation and Patenting activity of G1 Therapeutics Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of G1 Therapeutics Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
G1 Therapeutics Inc – Company Profile
G1 Therapeutics Inc (G1 Therapeutics) is a biopharmaceutical company. It discovers, develops and commercializes therapeutics for the treatment of cancer. The company offers pipeline products that include COSELA (trilaciclib), a CDK4/6 inhibitor to preserve hematopoietic stem cell and immune system function during chemotherapy, lerociclib and G1T48, an oral selective estrogen receptor degrader. G1 Therapeutics discovers new small molecule-based methods that prevent the hematological side effects of cancer chemotherapy and exposure to ionizing radiation. The company also develops small molecules to...
Add to Basket -
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC (malignancy) originates in the tissues of the lungs or the cells lining the airways. Symptoms usually occur in the later stages of the disease, and include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness, and unintentional weight...